Lb Pharmaceuticals Inc (LBRX)

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is h...